DOCSLIB.ORG

Long-Term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long-Term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Long-term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Major Therapeutic Drug Therapeutic Drug Name Subclass Code Name Code Class Code 0100 0100 00165 BIER BLOCK 0100 01983 ANESTHETIC 0100 02396 VARICELLA VIRUS VACCINE 0117 00130 A-CAINE 0117 01154 XYLOCAINE/MARCAINE 0117 01261 RAVOCAINE 0117 01345 AMERICAINE FIRST AID SPRAY 0117 01348 AMERICAINE HEMORRHOIDAL 0117 01350 AMERICAINE LUBRICANT 0117 02295 ANUJECT 0117 02309 AXILLERY BLOCK 0117 02349 LIDOCAINE W/MARCAINE 0117 03000 AURASOL 0117 03313 EPIDURAL ANESTHESIA TRAY 0117 03417 CHIROCAINE 0117 04060 BENZOCOL 0117 04065 BENZODENT 0117 04685 SANCURA 0117 05035 BUPIVACAINE 0117 05120 BUTESIN PICRATE 0117 05695 CARBOCAINE 0117 06855 CITANEST 0117 07110 COCAINE 0117 07385 COLREX TROCHE 0117 08115 CYCLAINE 0117 08170 CYLANA SYRUP 0117 08369 DALCAINE 0117 09390 DIBUCAINE 0117 09615 DILOCAINE 0117 10745 DURANEST 0117 10750 DURANEST HCL W/EPINEPHRINE 0117 11535 EPINEPHRICAINE 0117 12120 F-E-P 0117 12855 FOILLE 0117 13345 GENTZ WIPE 0117 13595 GLY-OXIDE 0117 14730 HURRICAINE 0117 17465 LIDA-MANTLE 0117 17485 LIDOCAINE 0117 17490 LIDOCAINE HCL 0117 17495 LIDOCAINE HCL W/EPINEPHRINE 0117 17500 LIDOJECT 0117 17833 LOCAL ANESTHETIC April 2007 1 Long-term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Major Therapeutic Drug Therapeutic Drug Name Subclass Code Name Code Class Code 0100 0117 18395 MARCAINE 0117 18400 MARCAINE HCL W/EPINEPHRN 0117 18585 MEDI-QUIK SPRAY 0117 20810 NERVOCAINE 0117 20815 NESACAINE 0117 21500 NOVOCAIN 0117 21565 NULICAINE 0117 21675 NYRAL 0117 21845 OPHTHETIC 0117 21930 ORABASE W/BENZOCAINE PASTE 0117 21935 ORACIN 0117 22165 OTIC PLAIN DROPS 0117 23010 PAZO HEMORRHOID 0117 23460 PERIFOAM 0117 24055 PHILJECT 0117 24411 POLOCAINE 0117 24555 PONTOCAINE 0117 24560 PONTOCAINE HCL 0117 24565 PONTOCAINE HCL NIPHANOID 0117 24570 PONTOCAINE W/DEXTROSE 0117 24803 PRAX LOTION 0117 25185 PROCAINE 0117 25485 PROPARACAINE 0117 25810 PYRIDIUM 0117 26210 RECTAL MEDICONE 0117 27740 SEMETS TROCHE 0117 27816 SENSORCAINE 0117 27817 SENSORCAINE S-D W/EPINEPHRINE 0117 27818 SENSORCAINE W/DEXTROSE 0117 29070 SPEC-T ANESTHETIC 0117 29073 SPEC-T DECONGESTANT 0117 29370 STERA-FORM 0117 31025 TETRACAINE 0117 31030 TETRACAINE HCL 0117 32645 TRONOTHANE 0117 33060 ULTRACAINE 0117 34195 VIO-HYDROSONE 0117 34200 VIO-PRAMOSONE 0117 35070 XYLOCAINE HCL 0117 35075 XYLOCAINE HCL W/DEXTROSE 0117 35080 XYLOCAINE HCL W/EPINEPHRINE 0117 35085 XYLOCAINE VISCOUS 0117 41500 SPECT-T COUGH SUPPRESSANT April 2007 2 Long-term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Major Therapeutic Drug Therapeutic Drug Name Subclass Code Name Code Class Code 0100 0117 41715 TRONOLANE 0117 41775 XYLOCAINE W/GLUCOSE 0117 42273 CHLOROPROCAINE 0117 42290 DUO-TRACH 0117 89014 BUPIVACAINE W/EPINEPHRINE 0117 89045 LIDOCAINE HCL VISCOUS 0117 89048 MEPIVICAINE HCL 0117 93125 PRAMEGEL 0117 93164 VAGISIL 0117 93403 ITCH-X 0117 93429 INJECTION (EPIDURAL) 0117 93430 INJECTION (GANGLION/NERVE BLOCK) 0117 97061 NAROPIN 0117 99007 ROPIVACAINE HCL 0117 99109 BUFFERED LIDOCAINE 0117 99117 LIDOCAINE BICARBONATE 0117 99154 ISOCAINE HCL 0118 01378 AMIDATE 0118 02068 BARBITURATES 0118 02349 LIDOCAINE W/MARCAINE 0118 02362 PROPOFOL W/LIDOCAINE 0118 06525 CHLOROFORM 0118 11875 ETHER 0118 11900 ETHRANE 0118 12775 FLUOTHANE 0118 12893 FORANE ANESTHETIC 0118 14055 HALOTHANE 0118 15560 INAPSINE 0118 16580 KETAJECT 0118 16585 KETALAR 0118 16590 KETAMINE 0118 21195 NITROUS OXIDE 0118 23300 PENTHRANE 0118 23315 PENTOTHAL 0118 30230 SURITAL 0118 31505 THIOPENTAL 0118 93262 MIDAZOLAM HCL 0118 93337 PROPOFOL 0118 93345 DIPRIVAN 0118 95055 DESFLURANE 0118 95058 ISOFLURANE 0118 95063 SUPRANE 0118 96060 SEVOFLURANE April 2007 3 Long-term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Major Therapeutic Drug Therapeutic Drug Name Subclass Code Name Code Class Code 0100 0118 96062 ULTANE 0118 97099 GENERAL ANESTHESIC 0118 99200 METHOHEXITAL 0119 00200 MEPERIDINE HCL 0119 00269 SUCCINYLCHOLINE CHLORIDE 0119 01975 ANECTINE 0119 02935 ATROPINE & PHENOBARBITAL 0119 02940 ATROPINE 0119 02943 ATROPINE AND DEMEROL 0119 02950 ATROPINE SULFATE 0119 02955 ATROPINE SULFATE & MEPERIDINE HCL 0119 03307 ORALET 0119 05710 CARBON DIOXIDE 0119 06995 CLORAZINE 0119 07650 CORAMINE 0119 10235 DOPRAM 0119 20085 MYLAXEN 0119 20740 NEOSTIGMINE METHYLSULFATE 0119 21040 NIKETHAMIDE 0119 22315 OXYGEN 0119 23005 PAVULON 0119 25950 QUELICIN 0119 29660 SUCCINYLCHOLINE 0119 29670 SUCOSTRIN 0119 41185 NORCURON 0119 92068 NUROMAX 0119 92119 DOXACURIUM 0119 93021 ARDUAN 0119 93096 MIVACRON 0119 93448 VECURONIUM 0119 95035 ATRACURIUM 0119 95040 MIVACURIUM 0119 95065 ZEMURON 0119 97084 ROCURONIUM 0119 97133 NIMBEX 0119 99123 MORPHINE SULFATE 0119 99196 CISATRACURIUM BESYLATE 0120 02391 NITRIC OXIDE 0120 02392 INOMAX 0120 05710 CARBON DIOXIDE 0120 21155 NITROGEN 0120 22315 OXYGEN 0121 00004 LIDODERM PATCH April 2007 4 Long-term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Major Therapeutic Drug Therapeutic Drug Name Subclass Code Name Code Class Code 0100 0121 00077 ZILACTIN-L 0121 00173 ELA-MAX 0121 00219 DYCLONINE HCL 0121 01156 MARCAINE/KENALOG 0121 01335 AMERICAINE 0121 02046 LAT 0121 02272 LANACANE 0121 03281 ANESTACON 0121 03317 XYLOCAINE W/ BICARBONATE 0121 04128 MYLANTA/BENADRYL TOPICAL SOLUTION 0121 05035 BUPIVACAINE 0121 06180 CETACAINE 0121 06470 CHLORASEPTIC 0121 06475 CHLORASEPTIC CHILDREN'S 0121 06480 CHLORASEPTIC DM 0121 06485 CHLORASEPTIC GEL 0121 06510 CHLOROBUTANOL 0121 07915 COUGH SILENCERS 0121 08965 DERMAREX 0121 14903 HYDROCORT 0121 19670 MOTIC SOLUTION 0121 21590 NUPERCAINE 0121 28740 SOLARCAINE 0121 99127 LIDOCAINE/EPINEPHRINE/TETRACAINE 0123 02310 ANUSOL 0123 25250 PROCTOFOAM 0200 0200 95034 ANTIDOTE 0281 00258 ETHYOL 0281 00286 ZINECARD 0281 01238 AMIFOSTINE 0281 01241 EDETATE CALCIUM DISODIUM 0281 02175 ANTILIRIUM 0281 02278 NATREXONE HCL 0281 03276 SUBOXONE 0281 03387 PRALIDOXIME CHLORIDE 0281 03405 SYPRINE 0281 03422 DESFERRIOXAMINE 0281 03475 BAL IN OIL 0281 04477 N-ACETYLCYSTEINE 0281 04501 MESNEX 0281 04506 DEXRAZOXANE 0281 05420 CALCIUM DISODIUM VERSENATE April 2007 5 Long-term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Major Therapeutic Drug Therapeutic Drug Name Subclass Code Name Code Class Code 0200 0281 06285 CHEALAMIDE 0281 08060 CUPRIMINE 0281 08075 CYANIDE ANTIDOTE PACKAGE 0281 08840 DEPEN 0281 09015 DESFERAL 0281 09965 DISOTATE 0281 10988 EDETATE DISODIUM 0281 11335 ENDRATE 0281 16455 KAYEXALATE 0281 17895 LORFAN 0281 18580 MEDI MARKER 0281 19160 METHYLENE BLUE 0281 20310 NARCAN 0281 20313 NARCOTIC ANTAGONIST 0281 23210 PENICILLAMINE 0281 25595 PROTAMINE SULFATE 0281 25615 PROTOPAM 0281 28650 SODIUM NITRITE 0281 28705 SODIUM VERSENATE 0281 32017 TREXAN 0281 41770 WELLCOVORIN 0281 60390 CUPRID 0281 60450 DIGIBIND 0281 60995 NALOXONE HCL 0281 92026 EDTA 0281 93094 ROMAZICON (MAZICON) 0281 93188 NALTREXONE 0281 93423 SUCCIMER 0281 94189 FLUMAZENIL 0281 96089 DEFEROXAMINE 0281 97109 REVIA 0281 98091 CHEMET 0283 06265 CHARCOCAPS 0283 06270 CHARCODATE 0283 15810 IPECAC 0283 16245 K-PHOS 0283 24380 POISON ANTIDOTE KIT 0283 28455 SODIUM BICARBONATE 0283 40120 ARM-A-CHAR 0283 40325 CHARDOSE 0283 89016 CHARCOAL, ACTIVATED W/ SORBITOL 0283 92002 ACTIDOSE-AQUA 0283 98081 REVEX April 2007 6 Long-term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Major Therapeutic Drug Therapeutic Drug Name Subclass Code Name Code Class Code 0200 0283 98122 ACTIDOSE WITH SORBITOL 0283 99052 ACTIVATED CHARCOAL 0285 01093 BOTOX 0285 02235 ANTIVENIN SPIDER BITE 0285 02240 ANTIVENIN SNAKE BITE 0285 03079 CROFAB 0285 03743 BEE STING ANTIVENIN 0285 04501 MESNEX 0285 60090 ANTIVENIN (LATRODECTUS MACTANS) 0285 60095 ANTIVENIN CROTALIDAE POLYVALENT 0285 93198 OCULINUM 0285 93232 BOTULISM TOXIN 0285 93364 ANTITOXIN 0285 93454 BOTULISM ANTITOXIN 0300 0300 00236 SBE PROPHALAXIS 0300 01286 ANTIMICROBIAL 0300 02158 ANTIBIOTIC AGENT 0300 03221 ENDOMYCIN 0300 03432 SULFAMETIN 0300 04437 URELLE 0300 19555 MITY-MYCIN 0300 35455 ANTIINFECTIVE AGENT 0300 93365 MITOXANTRONE 0300 99141 PIN-X 0346 00009 BICILLIN L-A 0346 00135 A-CILLIN 0346 00194 PENICILLIN G BENZATHINE & PROCA 0346 01053 AMPICILLIN AND SULBACTAM 0346 01054 TICARCILLIN AND CLAVULANATE POTASSIUM 0346 01203 BACILLIN C-R 0346 01315 AMCILL 0346 01630 AMOXICILLIN 0346 01635 AMOXICILLIN TRIHYDRATE 0346 01640 AMOXIL 0346 01680 AMPI-CO 0346 01685 AMPICILLIN 0346 01690 AMPICILLIN TRIHYDRATE 0346 02047 AUGMENTIN ES 0346 02161 PRINCIPEN 0346 02987 AUGMENTIN 125 0346 03081 AMOXICILLIN AND CLAVULANATE POTASSIUM 0346 03109 AUGMENTIN XR April 2007 7 Long-term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name Major Therapeutic Drug Therapeutic Drug Name Subclass Code Name Code Class Code 0300 0346 03128 AZLIN 0346 03331 AMOXICOT 0346 03425 BACTOCILL 0346 03741 BEEPEN VK 0346 04180 BETAPEN-VK 0346 04235 BICILLIN 0346 04240 BICILLIN C-R 0346 04528 TAZOBACTAM 0346 04531 SULBACTAM SODIUM STERILE 0346 05690 CARBENICILLIN 0346 06000 CELBENIN 0346 06963 CLOXACILLIN 0346 07015 CLOXAPEN 0346 08030 CRYSTICILLIN 0346 08113 CYCLACILLIN 0346 08130 CYCLAPEN 0346 09433 DICLOXACILLIN 0346 10705 DURACILLIN 0346 10820 DYCILL 0346 10845 DYNAPEN 0346 13350 GEOCILLIN 0346 13355 GEOPEN 0346 16235 K-PEN 0346 16555 KESSO-PEN 0346 17005 LANACILLIN VK 0346 17270 LEDERCILLIN VK 0346 18095 M-CILLIN 0346 19263 MEZLIN 0346 20175 NAFCILLIN 0346 20218 NALLPEN 0346 21795 OMNIPEN 0346 22233 OXACILLIN 0346 22935 PATHOCIL 0346 23185 PEN-VEE K 0346 23195 PENAMP 0346 23200 PENAPAR VK 0346
Load more

Recommended publications
  • A Study Into the Localized Corrosion of Magnesium Alloy Magnox Al-80
    A Study into the Localized Corrosion of Magnesium Alloy Magnox Al-80 Ronald N. Clark‡*, James Humpage**, Robert Burrows*, Hugh Godfrey***, Mustufa Sagir****, Geraint Williams** ‡Corresponding author. E-mail: [email protected]. *National Nuclear Laboratory, Unit 102B, Sperry Way, National Nuclear Laboratory, Stonehouse, GL10 3UT, UK **Swansea University, Materials Research Centre, Bay Campus, Fabian Way, Crymlyn Burrows, Swansea, SA1 8EN, Wales, UK ***National Nuclear Laboratory, Workington Laboratory, Havelock Road, Derwent Howe, Workington, Cumbria, CA14 3YQ, UK ****Sellafield Limited, Hinton House, Birchwood Park Avenue, Risley, Warrington, Cheshire, WA3 6 GR, UK [email protected] [email protected] [email protected] [email protected] [email protected] ABSTRACT Magnesium (Mg) non-oxidizing alloy, known as Magnox, was historically used as a fuel cladding material for the first-generation of carbon dioxide (CO2) gas-cooled nuclear reactors in the UK. Waste Magnox is currently stored in cooling ponds, pending final disposal. The corrosion resistance of Mg and its alloys is relatively poor, compared to modern cladding materials such as zirconium (Zr) alloys, so it is important to have a knowledge of the chloride concentration/pH dependence on breakdown and localized corrosion characteristics prior to waste retrievals taking place. Our results show that Magnox exhibits passivity in high pH solutions, with charge transfer resistance and passive film thicknesses showing an increase with immersion time. When chloride is added to the system the higher pH maintains Magnox passivity, as shown through a combination of potentiodynamic and time-lapse/post corrosion imaging experiments. Potentiodynamic polarization of Magnox reveals a -229 mV-decade linear dependence of breakdown potential with chloride ion concentration.
    [Show full text]
  • In Vivo Evaluation of Ixabepilone (BMS247550), a Novel Epothilone B Derivative, Against Pediatric Cancer Models Jennifer K
    Cancer Therapy: Preclinical In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models Jennifer K. Peterson,1Chandra Tucker,1Edward Favours,1PamelaJ. Cheshire,1Jeremy Creech,1 Catherine A. Billups,2 Richard Smykla,3 Francis Y.F. Lee,3 and Peter J. Houghton1 Abstract Purpose:Vinca alkaloids, agents that cause depolymerization of microtubules, are highly active in treatment of many pediatric cancers. In contrast, taxanes, agents that stabilize microtubules, are far less effective against the same cancer types.The purpose of the current study was to evaluate the antitumor activity of ixabepilone, an epothilone B derivative representing a new class of microtubule-stabilizing antimitotic agent in a wide variety of pediatric solid tumor models. Experimental Design: Ixabepilone was administered i.v. every 4 days for three doses to scid mice bearing s.c. human rhabdomyosarcoma (three lines), neuroblastoma (four),Wilms’ tumors (six), osteosarcoma (four), or brain tumors (seven).Tumor diameters were measured weekly, and tumor growth or regressions were determined. Pharmacokinetic studies were done following a single administration of drug at the maximum tolerated dose (MTD) level (10 mg/kg). Results: At the MTD (10 mg/kg), ixabepilone induced objective responses (all tumors in a group achieved z50% volume regression) in three of three rhabdomyosarcoma lines, three of five neuroblastomas, six of seven Wilms’ tumor models, two of six osteosarcoma, and four of eight brain tumor models. However, the dose-response curve was steep with only 2 of 19 tumors models regressing (z50%) at 4.4 mg/kg. In comparison, paclitaxel administered at the MTD on the same schedule failed to induce objective regressions of three tumor lines that were highly sensitive to treatment with ixabepilone.
    [Show full text]
  • 2701.Full-Text.Pdf
    Cancer Therapy: Clinical The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development Sanjay Goel,1Marvin Cohen,4 S. Nilgu« n C¸ o« mezoglu,4 Lionel Perrin,5 Franc¸ois Andre¤ ,5 DavidJayabalan, 1Lisa Iacono,4 Adriana Comprelli,4 Van T. Ly,4 Donglu Zhang,4 Carrie Xu,4 W. Griffith Humphreys,4 Hayley McDaid,1, 2 Gary Goldberg,1, 3 Susan B. Horwitz,1, 2 andSridhar Mani 1 Abstract Purpose:To determine if ixabepilone is a substrate for cytochrome P450 3A4 (CYP3A4) and if its metabolism by this cytochrome is clinically important, we did a clinical drug interaction study in humans using ketoconazole as an inhibitor of CYP3A4. Experimental Design: Human microsomes were usedto determine the cytochrome P450 enzyme(s) involvedin the metabolism of ixabepilone. Computational docking (CYP3A4) studies were done for epothilone B and ixabepilone. A follow-up clinical study was done in patients with cancer to determine if 400 mg/d ketoconazole (inhibitor of CYP3A4) altered the pharmacokinet- ics, drug-target interactions, and pharmacodynamics of ixabepilone. Results: Molecular modeling and human microsomal studies predicted ixabepilone to be a good substrate for CYP3A4. In patients, ketoconazole coadministration resulted in a maximum ixabepi- lone dose administration to 25 mg/m2 when comparedwith single-agent therapy of 40 mg/m 2. Coadministration of ketoconazole with ixabepilone resulted in a 79% increase in AUC0-1.The relationship of microtubule bundle formation in peripheral blood mononuclear cells to plasma ixabepilone concentration was well described by the Hill equation. Microtubule bundle formation in peripheral bloodmononuclear cells correlatedwith neutropenia.
    [Show full text]
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • Dilantin (Phenytoin Sodium) Extended Oral Capsule Three Times Daily and the Dosage Then Adjusted to Suit Individual Requirements
    Dilantin® (Phenytoin Sodium) 100 mg Extended Oral Capsule DESCRIPTION Phenytoin sodium is an antiepileptic drug. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is sodium 5,5-diphenyl-2, 4-imidazolidinedione, having the following structural formula: Each Dilantin— 100 mg Extended Oral Capsule—contains 100 mg phenytoin sodium. Also contains lactose monohydrate, NF; confectioner’s sugar, NF; talc, USP; and magnesium stearate, NF. The capsule body contains titanium dioxide, USP and gelatin, NF. The capsule cap contains FD&C red No. 28; FD&C yellow No. 6; and gelatin NF. Product in vivo performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to Prompt Phenytoin Sodium Capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours. CLINICAL PHARMACOLOGY Phenytoin is an antiepileptic drug which can be used in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • WATTS 04-2013 P1 PARC Management Team / Bestuurspan Aug
    04-2013 WATTS Year 83 + 4m Monthly newsletter of the Pretoria Amateur Radio Club Maandelikse nuusbrief van die Pretoria Amateur Radio Klub. PARC, PO Box 73696, Lynnwood Ridge 0040, RSA web http://www.parc.org.za mail: [email protected] Bulletins: 145,725 MHz 08:45 Sundays/Sondae Relays: 1.840, 3.700, 7.066, 10.135, 14.235, 51.400, 438.825, 1297 MHz ZR6FD logo Activated frequencies are announced prior to bulletins Papier / Paper Drukwerk ZS6RH Swapshop: 2m and 7.066 MHz Live on-air after bulletins ZS6RH Bulletin repeats Mondays | herhalings : Maandae 2m 19:45 Another glimpse of the extensive facility operated by Iain-ZS5IE (more photos on QRZ.com) In this issue In hierdie uitgawe Next club events Fleamarkets at PMC Member news and activities Lede-nuus en Aktiwiteite Wed 1 May (public holiday) Sat 10 Aug Sat 7 Dec Technical Rig reviews Tegnies Club social at U.P. G7FEK limited space antenna Thursday 4 Apr 7pm Aluminium alloys Club committee meeting ● Page eight -- Bladsy agt Thursday 18 Apr 7pm WATTS 04-2013 p1 PARC Management team / Bestuurspan Aug. 2012 – Aug. 2013 Committee members Chairman, Contests Pierre Holtzhausen ZS6PJH [email protected] 012-655-0726 082-575-5799 Vice Chairman, SARL liason Fritz Sutherland ZS6SF [email protected] 012-811-3875 083-304-0028 Secretary, Clubs, Strategy Jean de Villiers ZS6ARA [email protected] 012-663-6554 083-627-2506 Treasurer, SARS Andre van Tonder ZS6BRC [email protected] 361-3292 082-467-0287 Rallies, Social Johan de Bruyn ZS6JHB [email protected] 012-803-7385 079-333-4107 Webmaster Graham Reid ZR6GJR [email protected] 083-701-0511 RAE, Bulletin co-ordinator Vincent Harrison ZS6BTY [email protected] 012-998-8165 083-754-0115 Repeaters, Technical Craig Symington ZS6RH [email protected] 081-334-6817 Technical, Kits.
    [Show full text]
  • Lecture 6 OTC GERD/Heartburn Meghji
    Lecture 6 OTC GERD/Heartburn Meghji GASTROESOPHAGEAL REFLUX DISEASE: ALARM SYMPTOMS & WHEN TO REFER: • “A condition that develops when the reflux • Chest pain: radiating pain to shoulders, neck, arm, SOB, sweating of stomach contents causes troublesome • Vomiting: continuous/recurrent symptoms and/or complications” • GI blood loss: hematemesis, melena WHY CHECK FOR ALARM SX? (Montreal Classification) • Dysphagia (difficulty swallowing), especially solids Symptoms could be due or lead to: • Most common symptoms for mild GERD: • Odynophagia (severe pain on swallowing) • Cardiac disease o Heartburn (burning sensation along • Unexplained weight loss > 5% • PUD esophagus) • Unexplained cough, wheezing, choking, hoarseness • Malignancy o Regurgitation (acid/bile that rises to • Age > 50 years old with new symptoms • Functional dyspepsia the back of the throat) • Severe symptoms (frequency, rating) • Biliary disease • Features: • Nocturnal symptoms • Other o May wax and wane • Failure of 2 week H2RA/PPI therapy o Worse when lying down, bending over, or after a meal NON-PHARMACOLOGICAL TX: GOALS OF THERAPY: • Avoid foods/beverages that worsen or trigger symptoms • Treat symptoms CAUSE IS MULTIFACTORIAL: • Eat small meals and chew food well (reduce/eliminate) • Relaxation/decreased integrity of the • Avoid exercise after meals • Reduce or prevent recurrence lower esophageal sphincter • Don’t lie down for 2-3 hours after eating • Prevent structural damage and • Increased lower abdominal pressure • Avoid tight clothing thus complications (e.g. ulcers)
    [Show full text]
  • THE SPECIFICITY of DRUG BINDING SITES on HUMAN SERUM ALBUMIN Ingvar Sjòholm
    THE SPECIFICITY OF DRUG BINDING SITES ON HUMAN SERUM ALBUMIN Ingvar Sjòholm Today, it is well established that the binding of drugs in serum will strongly influence the pharmacokinetic parameters of a drug, such as its distribution volume and clearance. It is also evident that the binding of the drug—in serum and elsewhere in the tissues—will have an influence on the duration and intensity of the pharmacological effect. Several excellent papers and reviews have dealt with these issues in recent years.1"** It is obvious that albumin, being the most abundant protein species in the extracellular fluids, is the most im- portant drug-binding protein, although other proteins can play a pharmacokinetic role. Thus, e.g., orosomucoid (aj-acid glyco- protein) can bind some basic and neutral drugs ,9 and lipoproteins some highly hydrophobic drugs.10 The primary structure of human serum albumin (HSA) is now known.1:L'^2 However, all efforts to study the three-dimensional structure by x-ray spectroscopy have hitherto failed, and a detailed knowledge of the mechanisms involved in the binding of drugs or endogenous compounds is still missing. The broad binding specificity of HSA is remarkable. Several compounds of widely different struc- ture can be bound with high affinity—e.g., fatty acids, bilirubin, tryptophan, as well as many drugs. It is also striking that different reports from quantitative studies on the binding of different com- pounds have shown varying results, which cannot be solely explained by technical problems or different experimental conditions. All avail- able information indicates that HSA is a highly "flexible" and "adapt- able" molecule, the structure of which can be strongly influenced by different "modulating" substances.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Himalayan Aromatic Medicinal Plants: a Review of Their Ethnopharmacology, Volatile Phytochemistry, and Biological Activities
    medicines Review Himalayan Aromatic Medicinal Plants: A Review of their Ethnopharmacology, Volatile Phytochemistry, and Biological Activities Rakesh K. Joshi 1, Prabodh Satyal 2 and Wiliam N. Setzer 2,* 1 Department of Education, Government of Uttrakhand, Nainital 263001, India; [email protected] 2 Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-256-824-6519; Fax: +1-256-824-6349 Academic Editor: Lutfun Nahar Received: 24 December 2015; Accepted: 3 February 2016; Published: 19 February 2016 Abstract: Aromatic plants have played key roles in the lives of tribal peoples living in the Himalaya by providing products for both food and medicine. This review presents a summary of aromatic medicinal plants from the Indian Himalaya, Nepal, and Bhutan, focusing on plant species for which volatile compositions have been described. The review summarizes 116 aromatic plant species distributed over 26 families. Keywords: Jammu and Kashmir; Himachal Pradesh; Uttarakhand; Nepal; Sikkim; Bhutan; essential oils 1. Introduction The Himalya Center of Plant Diversity [1] is a narrow band of biodiversity lying on the southern margin of the Himalayas, the world’s highest mountain range with elevations exceeding 8000 m. The plant diversity of this region is defined by the monsoonal rains, up to 10,000 mm rainfall, concentrated in the summer, altitudinal zonation, consisting of tropical lowland rainforests, 100–1200 m asl, up to alpine meadows, 4800–5500 m asl. Hara and co-workers have estimated there to be around 6000 species of higher plants in Nepal, including 303 species endemic to Nepal and 1957 species restricted to the Himalayan range [2–4].
    [Show full text]